Bill Proposes Offering Exclusivity For Novel Drug Co-Development
Executive Summary
Bill proposes six months’ extra marketing exclusivity to spur development of combinations of investigational drugs for serious diseases. Setting aside prospects for passage in an election season, the question is whether that will be enough to get pharma to buy into a risky development space and pioneer a new business model.
You may also be interested in...
FDA Antibiotic Task Force Developing Standards To Help Products GAIN Traction
Task force model emerging as agency’s standard approach to implementing statutory directives to enhance product development.
View From ICAAC: How Higher Prices Can Help Save Antibiotic R&D
At the annual anti-infectives meeting, experts consider revamping the business model to spur development of novel antibiotics, with cooperation of regulators in Europe and U.S.
Bristol/Roche Finally Start Combination Melanoma Trial
The drug makers, potential competitors, will study Bristol's CTLA-4 inhibitor Yervoy in combination with Roche's investigational BRAF inhibitor vemurafenib in metastatic melanoma.